Lichen International is a Cayman holding company whose China tax-consulting franchise lost pricing power, and the equity is now a cash-funded option on whether a new advisory-and-capital model can replace a commoditized book of work.
The load-bearing event of the past year is not the April results announcement. It is the sequence that funded survival after Nasdaq threatened to throw the name off the Capital Market. Management closed a registered direct sale in January, then executed a one-for-two-hundred reverse split in early March after a low-priced-stock delisting notice, then sold another large private block in September. Those raises, not operating cash, rebuilt the year-end cash pile. The mechanism is simple: the listed holdco sells paper to keep a labor-heavy consulting shop running while the old education-plus-consulting identity is retired.
The tension is that the same year that produced the cash also produced the going-concern language. Revenue fell by about two-fifths as former bookkeeping shops undercut fees and SME clients paid less. The cost base barely moved because headcount stayed in place, so gross margin compressed and overhead ate almost the entire top line. A reader who treats the cash balance as a fortress is reading the financing statement, not the franchise.
The next test sits in the first full year after the August education shutdown and the DeepSeek-branded tool build. Either Pre-IPO advisory and the new diagnosis products start to show up as mix, or the holdco returns to the equity window. That is the timing trigger, not another brand campaign.